Description of Capital Stock
General
The following is a summary of the rights of our common stock and preferred stock and related provisions of our Certificate of Incorporation, as amended (“Certificate of Incorporation”), and Amended and Restated By-laws (“By-laws”). For more detailed information, please see our Certificate of Incorporation and By-laws.
Authorized and Outstanding Capital Stock
Our authorized capital stock consists of 225,000,000 shares of common stock, par value $0.0001 per share, and 250,000 shares of preferred stock, par value $0.01 per share, issuable in one or more series designated by our board of directors, of which 105,875 shares of our preferred stock have been designated as 5% Series B Cumulative Convertible Perpetual Preferred Stock (“Series B Preferred Stock”) and 33,500 shares of our preferred stock have been designated as Series C Convertible Preferred Stock (“Series C Preferred Stock” and, such shares, the “Series C Preferred Shares”).
As of April 30, 2018, 84,898,762 shares of our common stock were issued and outstanding, 64,020 shares of our Series B Preferred Stock were issued and outstanding, and 14,548 shares of our Series C Preferred Stock were issued and outstanding. No other shares of our preferred stock were issued and outstanding.
As of April 30, 2018, there were 1,000,000 Class A Cumulative Redeemable Exchangeable Preferred Shares (the “Series 1 Preferred Shares”) of FCE Ltd. (our Canadian subsidiary) issued and outstanding, which are convertible into shares of our common stock.
As of April 30, 2018, there were outstanding options to purchase 327,890 shares of our common stock under our equity incentive plans, 3,104,838 outstanding restricted stock units granted to employees under our equity incentive plans, 1,571,271 shares of our common stock available for future issuance under our equity incentive plans, and 500,000 shares of our common stock available for future issuance under our employee stock purchase plan.
As of April 30, 2018, there were outstanding warrants to purchase up to 19,249,364 shares of our common stock. The exercise prices of these warrants range from $1.60 to $5.83 and the expiration dates range from January 2022 to May 2022.
As of April 30, 2018, we were obligated, if and when the holder exercises its conversion rights, to issue approximately 15,166 shares of our common stock upon conversion of the Series 1 Preferred Shares. As of April 30, 2018, we were obligated, if and when the holders exercise their conversion rights, to issue approximately 454,043 shares of our common stock upon conversion of the Series B Preferred Stock. As of April 30, 2018, the aggregate outstanding stated value of the Series C Preferred Shares totaled $14.5 million. If this amount is converted into our common stock at its initial conversion price of $1.84, we would issue 7,906,783 shares of common stock upon their conversion (without giving effect to any limitations on conversion).
As of April 30, 2018, there were 188 holders of record of our common stock.
Our common stock is traded on The Nasdaq Global Market under the symbol “FCEL.”
Common Stock
The description of our common stock is set forth under the heading “Description of Capital Stock,” beginning on page
16 of the accompanying prospectus.
Preferred Stock
Series C Preferred Shares
We issued an aggregate of 33,500 shares of our Series C Preferred Stock, $0.01 par value and $1,000 stated value per share, for net proceeds of $27.9 million on September 8, 2017. Each share of Series C Preferred Stock was sold at a price of $895.52 for gross proceeds of approximately $30.0 million. As of April 30, 2018, there were 14,548 shares of Series C Preferred Stock issued and outstanding.